Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026)
Avalo Therapeutics (AVTX) posted Net Cash Flow of $9.2 million for Q1 2026, up 182.18% on a QoQ basis from -$11.2 million in Q4 2025, and up 197.32% year-over-year from $3.1 million in Q1 2025.
Avalo Therapeutics (AVTX) Net Cash Flow (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Net Cash Flow history runs 13 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- Quarterly Net Cash Flow rose 197.32% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (down 769.78% YoY) and the FY2025 annual result came in at -$118.6 million, down 193.3% from the prior year.
- Net Cash Flow was $9.2 million for Q1 2026 at Avalo Therapeutics, up from -$11.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $102.8 million in Q1 2024 and bottomed at -$82.7 million in Q2 2025.
- A 5-year average of -$1.7 million and a median of -$9.5 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1444.51% — and 2024, when it surged 2784.25%.
- Avalo Therapeutics' Net Cash Flow stood at -$3.9 million in 2022, then increased by 28.33% to -$2.8 million in 2023, then jumped by 2004.7% to $52.7 million in 2024, then slumped by 121.27% to -$11.2 million in 2025, then surged by 182.18% to $9.2 million in 2026.
- Business Quant data shows AVTX's Net Cash Flow at $9.2 million in Q1 2026, -$11.2 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 9.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.20 Mn |
| Mar 31, 2026 | 9.20 Mn |
| Dec 31, 2025 | -11.20 Mn |
| Dec 31, 2025 | -11.20 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Jun 30, 2025 | -82.67 Mn |
| Jun 30, 2025 | -82.67 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | 52.67 Mn |
| Dec 31, 2024 | 52.67 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.76 Mn |
| Jun 30, 2024 | -16.76 Mn |
| Mar 31, 2024 | 102.77 Mn |
| Mar 31, 2024 | 102.77 Mn |
| Dec 31, 2023 | -2.77 Mn |
| Dec 31, 2023 | -2.77 Mn |